Hetero Labs Wins Approval To Sell COVID-19 Drug Favipiravir

Hetero Labs Ltd has received regulatory approval to sell its version of anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Wednesday, as coronavirus infections in India, the world's third worst-hit nation crossed 1.5 million. The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19 and will be available at drug stores from Wednesday, privately held Hetero said in a statement. Favipiravir ...